EU GMP audit delay for Ambernath facility
EU authority cited low manpower as reason for inability to provide immediate audit dates. Expected 3-4 months delay (Q1 FY27) could postpone regulated market traction for CDMO business.
SUPRIYA / bear-case history
Track the concerns that keep returning.
Supriya Lifescience · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
high
ATS-8 customer price acceptance uncertainty
Market not yet accepting $105+ import price levels. Large users targeted for export are already approved; domestic market ambiguity persists. No firm annual contracts in place—only volume commitments being signed.
DSM project revenue timing risk
Pharma validation completed in January; meaningful contribution pushed to H2 FY27 vs earlier H1 expectations. Protein project R&D completion in 3-4 months adds further timeline uncertainty.
Isambe greenfield timeline
Environmental clearance took 2.5 years to obtain. Blueprint finalization stage; 9-12 months before any meaningful disclosure possible. Long gestation period for new capacity.
Ambernath Revenue Contribution Delayed
Despite starting some revenue generation, Ambernath will only see full commercial impact in 2-3 years. Ambernath inventory has already added Rs 10-15 crore to working capital, pressuring cash conversion.
EU GMP and USFDA Audit Scheduling Uncertainty
EU GMP audit for Ambernath pushed to H2 FY27 with no confirmed dates; USFDA audit dates yet to be scheduled due to auditor unavailability. Without EU approval, liquid anesthetic formulation ramp-up is delayed 3-4 years.
Gross Margin Pressure from New Product Scale-ups
Management deflected questions on gross margin deterioration, attributing some EBITDA margin pressure to Ambernath expenses without revenue offset. New cardiovascular and anesthetic products scale through semi-regulated markets initially.
Working Capital Intensity Rising
Inventory days running at ~200 days for 2 years; net working capital extended to 170-180 days due to Ambernath inventory buildup and higher intermediate stocks for scaled-up products.